Note 12 - Revenues (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Years Ended December 31,
	2023		2022
United States	$	6,029,000	$	6,641,000
China		98,000		1,984,000
United Arab Emirates		570,000		–
Vietnam		225,000		515,000
Other		2,523,000		1,343,000
Total	$	9,445,000	$	10,483,000

	Year Ended December 31, 2023
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	4,970,000	$	232,000	$	–	$	5,202,000
BioArchive		1,484,000		1,361,000		–		2,845,000
X-Series		121,000		152,000		779,000		1,052,000
Other		288,000		–		58,000		346,000
Total	$	6,863,000	$	1,745,000	$	837,000	$	9,445,000

	Year Ended December 31, 2022
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	5,911,000	$	480,000	$	–	$	6,391,000
BioArchive		1,247,000		968,000		–		2,215,000
X-Series		654,000		190,000		285,000		1,129,000
Other		719,000		–		29,000		748,000
Total	$	8,531,000	$	1,638,000	$	314,000	$	10,483,000

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]

	Remainder of 2024		2025		2026		2027		2028 and beyond		Total
Service revenue	$	1,186,000	$	514,000	$	125,000		–	$	–	$	1,825,000
Device revenue (1)		41,000		–		–		–		–		41,000
Exclusivity fee		267,000		–		–		–		–		267,000
Clinical revenue		13,000		13,000		13,000		13,000		83,000		135,000
Total	$	1,507,000	$	527,000	$	138,000	$	13,000	$	83,000	$	2,268,000